NASDAQ:ILMN Illumina (ILMN) Stock Price, News & Analysis $135.60 +4.63 (+3.54%) (As of 12:28 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Illumina Stock (NASDAQ:ILMN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$133.88▼$136.1950-Day Range$114.49▼$135.9052-Week Range$89.00▼$148.19Volume386,034 shsAverage Volume2.03 million shsMarket Capitalization$21.60 billionP/E RatioN/ADividend YieldN/APrice Target$151.05Consensus RatingModerate Buy Company OverviewIllumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.Read More… War on Elon Escalates… (Ad)Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. Illumina Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 90th PercentileIllumina scored higher than 90% of companies evaluated by MarketBeat, and ranked 122nd out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingIllumina has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 12 buy ratings, 9 hold ratings, and 1 sell rating.Amount of Analyst CoverageIllumina has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Illumina's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth22.38% Earnings GrowthEarnings for Illumina are expected to grow by 22.38% in the coming year, from $3.62 to $4.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Illumina is -16.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Illumina is -16.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIllumina has a P/B Ratio of 3.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Illumina's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.81% of the outstanding shares of Illumina have been sold short.Short Interest Ratio / Days to CoverIllumina has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Illumina has recently increased by 6.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIllumina does not currently pay a dividend.Dividend GrowthIllumina does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.11 Percentage of Shares Shorted2.81% of the outstanding shares of Illumina have been sold short.Short Interest Ratio / Days to CoverIllumina has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Illumina has recently increased by 6.18%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.64 News SentimentIllumina has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Illumina this week, compared to 15 articles on an average week.Search InterestOnly 25 people have searched for ILMN on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Illumina insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.17% of the stock of Illumina is held by insiders.Percentage Held by Institutions89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Illumina's insider trading history. ILMN Stock News Headlines3 Genomics Stocks Transforming HealthcareSeptember 19 at 6:12 AM | stocknews.comIllumina, Inc. (NASDAQ:ILMN) Short Interest Up 6.2% in AugustSeptember 19 at 6:07 AM | americanbankingnews.comThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start with diversification and experience. Founded in 2005, this company serves a diverse and expansive customer base with more than 8,000 retail locations, including licensed cannabis dispensaries, smoke shops, and specialty retailers. September 19, 2024 | Greenlane (Ad)Illumina, Inc. Forecasted to Earn Q3 2025 Earnings of $1.12 Per Share (NASDAQ:ILMN)September 19 at 1:11 AM | americanbankingnews.comILMN Jan 2026 210.000 callSeptember 17 at 6:29 AM | ca.finance.yahoo.comILMN Dec 2024 210.000 callSeptember 17 at 6:29 AM | ca.finance.yahoo.comIllumina, Inc. (NASDAQ:ILMN): A Non-Tech Stock With Long-Term Investment PotentialSeptember 17 at 2:13 AM | insidermonkey.comVelsera Technology Paves the Way for Advanced Cancer Diagnostics with FDA Approval of Illumina TruSight™ Oncology Comprehensive IVDSeptember 16 at 12:06 PM | tmcnet.comSee More Headlines ILMN Stock Analysis - Frequently Asked Questions How have ILMN shares performed this year? Illumina's stock was trading at $139.24 at the beginning of the year. Since then, ILMN stock has decreased by 2.7% and is now trading at $135.46. View the best growth stocks for 2024 here. How were Illumina's earnings last quarter? Illumina, Inc. (NASDAQ:ILMN) announced its quarterly earnings results on Tuesday, August, 6th. The life sciences company reported $0.36 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.24. Illumina's revenue was down 5.4% compared to the same quarter last year. Does Illumina have any subsidiaries? Illumina subsidiaries include these companies: Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and others. Who are Illumina's major shareholders? Top institutional investors of Illumina include Baillie Gifford & Co. (3.52%), Bank of New York Mellon Corp (1.91%), Primecap Management Co. CA (1.52%) and Millennium Management LLC (0.93%). Insiders that own company stock include Susan H Tousi, Jacob Thaysen, Aimee L Hoyt, Charles Dadswell, Phillip G Febbo and Alexander Aravanis. View institutional ownership trends. How do I buy shares of Illumina? Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Illumina own? Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL) and Salesforce (CRM). Company Calendar Last Earnings8/06/2024Today9/19/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:ILMN CUSIP45232710 CIK1110803 Webwww.illumina.com Phone(858) 202-4500Fax858-202-4766Employees9,300Year Founded1998Price Target and Rating Average Stock Price Target$151.05 High Stock Price Target$242.00 Low Stock Price Target$100.00 Potential Upside/Downside+15.3%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)($8.15) Trailing P/E RatioN/A Forward P/E Ratio36.18 P/E GrowthN/ANet Income$-1,161,000,000.00 Net Margins-68.73% Pretax Margin-68.53% Return on Equity3.08% Return on Assets1.60% Debt Debt-to-Equity Ratio1.04 Current Ratio1.11 Quick Ratio0.86 Sales & Book Value Annual Sales$4.43 billion Price / Sales4.71 Cash Flow$3.76 per share Price / Cash Flow34.84 Book Value$36.18 per share Price / Book3.62Miscellaneous Outstanding Shares159,300,000Free Float159,029,000Market Cap$20.86 billion OptionableOptionable Beta1.15 Social Links Should I Buy Illumina Stock? ILMN Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, August 22, 2024. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com. Illumina Bull Case Here are some ways that investors could benefit from investing in Illumina, Inc.: Illumina's stock price has shown resilience, currently trading at $130.31, with a potential for growth based on recent performance. The company reported positive return on equity of 2.31%, indicating efficient use of shareholder funds to generate earnings. Recent institutional inflows from large investors demonstrate confidence in Illumina's future prospects. With a diverse range of genetic and genomic analysis solutions, Illumina is well-positioned to capitalize on the growing demand for such technologies. Analysts' consensus rating of "Moderate Buy" and an average price target of $151.10 suggest a positive outlook for the company. Illumina Bear Case Investors should be bearish about investing in Illumina, Inc. for these reasons: Illumina's quarterly revenue was down 5.4% compared to the same quarter last year, indicating a potential slowdown in growth. The company had a negative net margin of 28.71%, which may raise concerns about profitability and cost management. The stock's 50-day simple moving average is below the 200-day simple moving average, potentially signaling a bearish trend in the short to medium term. Debt-to-equity ratio of 0.26 may indicate higher financial leverage, increasing the company's risk profile. Market volatility and competition in the genetic and genomic analysis industry could pose challenges to Illumina's market share and growth trajectory. This page (NASDAQ:ILMN) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredTrump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absoluteDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Illumina, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Illumina With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.